Glurenorm

Glurenorm is a prescription medication that contains gliquidone, a second‑generation sulfonylurea, supplied as oral tablets (strength not specified). It belongs to the antidiabetic, oral hypoglycemic class and is marketed in the European Union. Glurenorm stimulates insulin release from pancreatic beta cells, helping lower blood glucose in patients with type 2 diabetes mellitus. It requires a doctor's prescription and medical supervision through regular follow‑up and dose adjustments as needed.

Glurenorm is indicated for the management of hyperglycaemia in adults with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

- As monotherapy in adults newly diagnosed with type 2 diabetes who have not reached glycaemic targets with diet and exercise alone. - In combination with metformin or other oral antidiabetics to enhance overall glucose lowering. - As an add‑on when other insulin secretagogues are insufficient. - For patients preferring a second‑generation sulfonylurea with a reduced hypoglycaemia risk versus first‑generation agents. - To help achieve individualized HbA1c goals within a broader diabetes care plan.

Glurenorm may cause adverse reactions typical of sulfonylureas. The frequency and severity of side effects vary among individuals.

Common: - Mild hypoglycaemia, especially if meals are skipped or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhoea. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient blurred vision. - Generalised fatigue or weakness.

Serious: - Severe hypoglycaemia leading to loss of consciousness or seizures. - Allergic reactions including skin rash, urticaria, or angio‑edema.

Before prescribing Glurenorm, clinicians should evaluate patient history and clinical conditions that may increase the risk of adverse outcomes.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Use caution in elderly patients due to heightened hypoglycaemia susceptibility. - Monitor blood glucose regularly, especially during therapy initiation or dose changes. - Evaluate for a history of cardiovascular disease, as sulfonylureas may affect cardiac ischemic preconditioning. - Avoid use in patients with known hypersensitivity to gliquidone or other sulfonylureas. - Consider pregnancy and lactation status; safety data are limited. - Review concomitant medications that could potentiate hypoglycaemia.

Glurenorm can interact with several drugs that alter glucose metabolism or affect sulfonylurea clearance.

Avoid: - Concurrent use with other insulin secretagogues (e.g., repaglinide, nateglinide) due to additive hypoglycaemia risk. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) which may increase gliquidone plasma levels.

Use with caution: - Beta‑blockers, which may mask hypoglycaemia symptoms. - Thiazide diuretics, which can raise blood glucose. - Corticosteroids or atypical antipsychotics that may elevate glucose levels. - Alcohol, which can potentiate hypoglycaemia, especially after a dose of Glurenorm.